IGF-1 LR3 (1mg)

IGF-1 LR3 is a synthetic analog of human insulin-like growth factor-1 engineered with an N-terminal extension (13 amino acids) and a glutamic acid substitution at position 3, resulting in significantly reduced binding affinity for IGF binding proteins. This modification extends the peptide's half-life from minutes (native IGF-1) to several hours and enhances systemic bioavailability. The prolonged circulation time permits once-daily administration protocols. Unlike native IGF-1, which requires frequent dosing, IGF-1 LR3 maintains more stable plasma levels. The peptide manifests anabolic and metabolic activities via binding to the IGF-1 receptor. Its insulin-like properties necessitate careful blood glucose management, especially during initial titration phases.

• Reconstitution: Add 3.0 mL of 0.6% acetic acid → ~0.333 mg/mL. ⚠️ Acetic acid only — BAC water does not properly dissolve IGF-1 LR3 due to its hydrophobic structure.
• Typical Daily Range: 20–50 mcg once daily subcutaneously (gradual titration).
• Storage: Lyophilized: freezer −20 °C; after reconstitution, refrigerate 2–8 °C; use within 30 days; avoid freeze-thaw.

1. ⚠️ Use 0.6% acetic acid exclusively — DO NOT use bacteriostatic water. IGF-1 LR3 is hydrophobic (83 amino acids) and does not properly dissolve at a neutral pH.
2. Draw 3.0 mL of 0.6% acetic acid with a sterile syringe.
3. Inject slowly down the side of the vial; avoid foaming; do not shake.
4. Gently swirl until fully dissolved into a clear solution (may take 2–3 minutes).
5. Note date of reconstitution and refrigerate at 2–8 °C, protecting from light.
6. Use within 30 days; for longer storage, prepare aliquots and freeze at −20 °C.

• Goal: Support anabolic processes and metabolic function via enhanced IGF-1 action with extended bioavailability.
• Schedule: Daily subcutaneous injections for 8 weeks (typical cycle); may be extended to 12 weeks.
• Storage: Lyophilized frozen at −20 °C; reconstituted refrigerated; avoid freeze-thaw cycles.
• Cycling: Common approach is 8 weeks on, 4–8 weeks off to prevent receptor desensitization.

• Initiation (Wk 1–2): 20 mcg daily to assess tolerance, particularly regarding blood glucose effects.
• Titration (Wk 3–4): Increase to 40 mcg daily if Wk 1–2 were well-tolerated without significant hypoglycemic symptoms.
• Maintenance (Wk 5–8): Maintain at 50 mcg daily; considered the conservative upper limit.
• Frequency: Once daily subcutaneously; timing is often with meals (morning or post-workout).
• Cycle Duration: 8 weeks is typical; 12-week protocols exist but may show diminished returns after Wk 6–8.
• Break between cycles: After a cycle (8 weeks), a 4–8 week washout period is recommended. This break prevents desensitization of IGF-1 receptors.

• Lyophilized: Store at −20 °C (or −80 °C optimally) in dry, dark conditions for up to 12 months.
• Reconstituted: Refrigerate at 2–8 °C immediately after mixing; use within 30 days.
• Extended Storage: Prepare sterile aliquots and freeze at −20 °C; stable for 3–6 months. Never re-freeze a thawed vial.
• Allow frozen vials to reach room temperature before opening; always check for clarity (discard if cloudy or particulate).

• Hypoglycemia Awareness: Be vigilant for signs of low glucose (tremors, dizziness, sweating); have fast-acting carbohydrates available.
• Timing with Meals: Administer with or immediately after food intake to mitigate insulin-like effects.
• Do not exceed conservative dosing: Doses above 50–60 mcg/day lack robust clinical documentation.

1. Biomolecules (MDPI) — IGF-1 and its monitoring in medical diagnostics and sport
   View Source
2. Dopinglinkki (FINCIS) — IGF-1 and LR3IGF-1: medical information and safety overview
   View Source
3. Mayo Clinic / IBM Micromedex — Mecasermin (subcutaneous): proper use and timing with meals
   View Source
4. Cell Sciences — Recombinant Human LR3 IGF-1: technical specifications for storage and stability
   View Source
5. Frontiers in Bioengineering & Biotechnology — IGF-1: a promising therapeutic target for peripheral nerve injury
   View Source